I agree that this site is using cookies. You can find further informations here.
X
Szubert, AJ
34  results:
Search for persons X
?
1

A479 MRD Studies in MM: Data from the MRC Myeloma IX Trial:

Owen, RG ; Rawstron, AC ; Drayson, MT...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S76 , 2009
Link: https://doi.org/10.1016/..
 
?
2

A546 MRC Myeloma IX: Preliminary Results from The Intensive..:

Owen, RG ; Child, JA ; Jackson, GH...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S84-S85 , 2009
Link: https://doi.org/10.1016/..
 
?
3

B455 A Molecular Characterization of 17p Deletion in Myelom..:

Boyd, KD ; Walker, BA ; Gonzalez, D...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S137 , 2009
Link: https://doi.org/10.1016/..
 
?
4

A346 Prospective Study of Serum FLC and Other M-Protein Ass..:

Drayson, MT ; Morgan, GJ ; Jackson, GH...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S56 , 2009
Link: https://doi.org/10.1016/..
 
?
5

A547 MRC Myeloma IX: Preliminary Results from the Non-Inten..:

Owen, RG ; Morgan, GJ ; Jackson, H...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S85 , 2009
Link: https://doi.org/10.1016/..
 
?
6

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarat..:

Waalewijn, H ; Szubert, AJ ; Wasmann, RE...
https://openaccess.sgul.ac.uk/id/eprint/115544/1/ciad267.pdf.  , 2023
Link: https://openaccess.sgul...
 
?
7

COVAC1 phase 2a expanded safety and immunogenicity study of..:

Szubert, AJ ; Pollock, KM ; Cheeseman, HM...
https://openaccess.sgul.ac.uk/id/eprint/115173/1/COVAC1%20phase%202a%20expanded%20safety%20and%20immunogenicity%20study%20of%20a%20self-amplifying%20RNA%20vaccine%20against%20SARS-CoV-2.pdf.  , 2023
Link: https://openaccess.sgul...
 
?
8

When should factorial designs be used for late-phase random..:

White, IR ; Szubert, AJ ; Choodari-Oskooei, B..
https://ora.ox.ac.uk/objects/uuid:54b24779-869f-4395-b2ad-27ffe30936ba.  , 2023
Link: https://ora.ox.ac.uk/obj..
 
?
9

Safety and immunogenicity of a self-amplifying RNA vaccine ..:

Pollock, KM ; Cheeseman, HM ; Szubert, AJ...
https://discovery.ucl.ac.uk/id/eprint/10142501/1/1-s2.0-S2589537021005435-main.pdf.  , 2022
Link: https://discovery.ucl.ac..
 
?
10

COVAC1 phase 2a expanded safety and immunogenicity study of..:

Szubert, AJ ; Pollock, KM ; Cheeseman, HM...
EClinicalMedicine.  , 2022
Link: http://hdl.handle.net/10..
 
?
11

Safety and immunogenicity of a self-amplifying RNA vaccine ..:

Pollock, KM ; Cheeseman, HM ; Szubert, AJ...
https://openaccess.sgul.ac.uk/id/eprint/114347/1/1-s2.0-S2589537021005435-main.pdf.  , 2022
Link: https://openaccess.sgul...
 
?
12

The impact of viraemia on inflammatory biomarkers and CD4 c..:

Prendergast, AJ ; Szubert, AJ ; Pimundu, G...
https://discovery.ucl.ac.uk/id/eprint/10111394/9/Walker_The_impact_of_viraemia_on_inflammatory_biomarkers.2.pdf.  , 2021
Link: https://discovery.ucl.ac..
 
?
13

The impact of viraemia on inflammatory biomarkers and CD4 c..:

Prendergast, AJ ; Szubert, AJ ; Pimundu, G...
doi:10.1097/QAD.0000000000002916.  , 2020
Link: https://doi.org/10.1097/..
 
?
14

Cotrimoxazole reduces systemic inflammation in HIV infectio..:

Bourke, CD ; Gough, EK ; Pimundu, G...
doi:10.1126/scitranslmed.aav0537.  , 2019
Link: https://doi.org/10.1126/..
 
?
15

Inflammatory biomarkers in HIV-infected children hospitaliz..:

Prendergast, AJ ; Berejena, C ; Pimundu, G...
https://discovery.ucl.ac.uk/id/eprint/10064304/8/Prendergast_181123%20ARROW%20SAM%20inflammation%20CLEAN.pdf.  , 2019
Link: https://discovery.ucl.ac..
 
1-15